Introduction
Zolpidem (CAS 82626-48-0)i sasedativem edicine that hasbeen prescribed forinsomniaformanyy ears.Itinducessleep byactivating GABA(A)receptors in the brain whicharei nhibitory macromolecularcomplexest hat mediatesedative,a nticonvulsant,a nxiolytica nd myorelaxanteffects [1] .Zolpidem isac hemicallydistinct imidazopyridine thatbindspreferentiallyt othe omega1subunitof the GABA(A)receptor [2, 3] .
The medicall iteraturecontainss everalwell-documented reports of individualp atients withbrain damage who improved when theyt ook zolpidem. In2000 the first casereport of anunexpected transientawareness afterz olpidem describesayoung male patientcategorized tothe vegetativestateafteratraumaticb rain injury 3years earlier,who regained consciousness 30 min afters wallowing a10mg zolpidem tablet [4] . Severalsimilarcaseshavebeen reported sincethen [5] [6] [7] [8] .Zolpidem hasalsobeen reported toi mproven eurologicalf unction in fullyconscious patients withsevere neurologicald isabilitiesduetostroke,traumaticb rain injury and othercauses [9] [10] [11] [12] .
Insome reports,S PECT and PET scansdetected an improvementof suppressed cerebralperfusion and metabolismi nthe brain afterz olpidem [4, 6, 11] .Animal studieshavealsodocumented normalization of cerebral perfusion in injured brain afterz olpidem [13] .
The aim of thisstudywastoevaluatethe effectof zolpidem in consecutivepatients withneurologicaldisability afterbrain damage,using established clinicalrating scalesand 99m TcHMPAO brain SPECT scans.
Abstract
Previous reports documentt ransientimprovements afterdailyz olpidem (CAS 82626-48-0)i np atients withbrain damage. Thismulti-patients tudyevaluates the responsetozolpidem in neurologicallydisabled patients,using 99m TcHMPAO brain SPECT scansand clinicalrating scales.
Method: 23 of 41 consecutiveadult patients,a tleast 6monthsafterbrain damage werei dentified asneurologically disabled patients bys coring less than 100/100 on the Barthel Index.Causesof theirbrain damage included stroke (n =12),traumaticb rain injury (n =7), anaphylaxis(n =2),drugsoverdose (n =1)and birthi njury (n =1). The selected 23 patients hadab aseline 99m TcHMPAO brain SPECT scanbefore starting dailyz olpidem therapyand a second withintwoweeksof therapy,performed 1hafter10mg oralzolpidem. Scansw ered esignated asimproved when atleast twoo fthree assessors detected improvementafterz olpidem.The rest weredesignated non improved.Afterfour monthsdailyz olpidem therapy,patients wererated on the TinettiFallsEfficacy Scale (TFES)beforeand afterz olpidem. The TFES ratingsw erecompared using a Wilcoxon non parametricsigned rank test.Scani mprovers werecompared with non improvers,using atwosample tt est withunequalvariance.
Results: Meanoverall improvement afterz olpidem on TFESwas11.3%,from 73.4/100 to62.1/100 (p =0.0001). 10/23 (43%) patients improved on SPECT scan afterz olpidem. TheirmeanTFES improvementw as19.4 %( ±16.75) compared with5 .08% (± 5.17)i n1 3/23 non improvers (p =0.0081).
Conclusion: Thisprospectivestudy addsfurtherevidencetop revious reports of zolpidem efficacyin patients withestablished brain damage.
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Projectdetails
The studyw asr egistered through the NuclearMedicine Departmentof the University of Pretoria(UP)asanMMed project of one of the participating coauthors (NEN)and approved by the UP ethicscommittee underprojectr egistration number 80/2008.
2.2Patientpopulation
During the last twoyears,a ll consecutiveadultpatients with brain damage of atleast 6monthsduration who applied toa coauthor'spractice( HWN)f orz olpidem therapyw ereasked if theyw anted top articipatei nthe study.All wereg iven full information regarding zolpidem and brain SPECT procedures and ample time toconsidert he information beforetheyand theirrelativesgavewritten consent.All consented patients were fullyexamined clinically.Therewere4 1p atients who could participateinthe study.
2.3Patients election
Todetermine neurologicaldisability,all patients wererated according tothe Barthel Indexafterinterviews withtheircarers and families [14] .The top possible scoreo nthisindexis100/ 100.23/41 patients scored less thanthe possible 100/100. These23/41 patients wereclassed asneurologicallydisabled patients and selected forfurthers tudy.Therewere9f emale and 14 male patients,a ged between 20 and 77 (mean4 5.8). Causesof theirbrain damage included stroke (n =12),traumaticb rain injury (n =7),a naphylaxis(n =2),drugsoverdose (n =1)and birthinjury (n =1). Four wereinthe MinimallyConscious State,one hadthe Locked in Syndrome and the rest were FullyConscious.
Clinicalrating beforeand afterz olpidem
Zolpidem tablets (10mg,S tilnox,L ot8-64,expiry dateJuly 2012),supplied bySanofi AventisSouthAfrica (Pty)Ltd,M idrand,S outhAfrica werep rovided byt he AcadiaP harmacyin PollockPark,S prings,S outhAfrica.The 23 selected patients took 10mg zolpidem every morning foratleast four months. Onf ollowu p,theyw erescored on the TinettiFallsEfficacy Scale (TFES)whichm easuresconfidencei nactivitiesof daily living. The scoresw erebased on interviews withtheirfamily and carers who rated the patient'sconfidenceaccording tothe Tinetticriteriaa tbaseline beforezolpidem and afterz olpidem therapy [15] .Patients and carers wereasked whetheranysedation wasexperienced afterz olpidem.
SPECT scanp rocedureand preparation
All selected patients hadab aseline Forprivateorinternal corporateuseonly Table 1 :T he gender,a ge,c ausesof brain damage (Diagn.:C VA -Stroke,T BI -TraumaticB rain Injury,A naph -Anaphylaxis, BirthInj -BirthInjury,D rugsOD -DrugsOverdose),the Barthel Index(BI),the TinettiFallsEfficacyScale beforezolpidem (TFES),the TFES afterz olpidem (TFESzlp),the change in the TFES afterz olpidem (change),the stateo fconsciousness (MCSMinimallyConscious State,LIS -Locked in Syndrome,FC-FullyConscious),brain SPECT scanresults (I-Improvers,NI-Non Improvers)and sedation effect(Sed,y-yes,n-no) for23neurologicallydisabledpatients (Pt)scoring less than100/100 on the BI, atleast sixmonthsaftertheirbrain damage. Iy  mn  M42Anaph  60  867 016FC  NI  y  kcM  65CVA  30  54  4212FC  NI  n  beM22  TBI  0100  9010MCS  NI  n  mj  M38CVA  95  36  26  10FC  In  oaF  34TBI  51 00  937  LIS  NI  y  IpM53CVA  9044  37  7FC  NI  y  raF  48  Anaph  10100  95  5MCS  NI  y  df  M27  TBI  15  91  865FC  NI  y  ugM39TBI  20  95  932  FC  NI  y  rkM53CVA  807 1692FC  NI  n  de  M32  TBI  0100  100  0FC  In  ImF72  CVA  10100  100  0FC  NI  n  he  F20  BirthInj  45  66  66  0FC  NI  n  ktM65CVA  60  36  36  0FC  Iy  vaF  77  CVA  7562  62  0FC  Iy  jaM  23  TBI  803 4340FC  NI  n  ac  F38DrugsOD  0100  100  0MCS  NI  y   perframe and less than1 9cmradiald istanceata140keV photo-peaksymmetrical20 %window,using lowenergyhigh resolution collimators.
2.6Acquisition protocol
2.7Image processing
Imagesw erereconstructed on ane -softv iewing station using filtered backp rojectionand Metz filtering. Coronal,sagittal and transverseimageswereconstructed withsimilaralignment in the baseline and post zolpidem images.
Interpretation of the brain SPECT scans
The scanswereassessed visuallybyt hree independent,experienced nuclearmedicinep hysiciansw ho wereunawareo fthe scan'stiming in relation tothe zolpidem treatment.Scanswere presented tothem asw ithin-patientpairs,b ut in arandom orderin relation tozolpidem. The assessors wererequired to statewhichscand epicted less damage,b ased on lesion size and uptake,orw hethert herewasno difference. All patients who wererated asbetter(less damage)onthe zolpidem SPECT byt woo rmoreassessors wered esignated improvers while thoserated asbetteron the baseline SPECT or"no different" weredesignated non improvers.When therewasno agreement between assessors theywereallowed toreachaconsensusopinion while remaining blinded tozolpidem treatment(4/23 patients in total).
Statisticalanalysis
The statisticalanalysiswascompleted byDrOlorunjufrom the MRC biostatisticsdepartmentin Pretoria, SA.The overall TFES scorewascompared beforeand afterz olpidem in all patients using the non parametricW ilcoxon signed rank test.The TFES scoresin patients designated asimproved and non improved afterzolpidem according totheirbrain SPECT scanswerecompared,using atwosample tt est withunequalvariance. Table 1shows the gender,a ge,c ausesof brain damage, the Barthel Index(BI),the TFES scorebeforeand after zolpidem,the change in the TFES score,the stateo f consciousness (MCS -MinimallyConscious State,L ISLocked in Syndrome,F C-FullyConscious)the Brain SPECT scanresults (I-Improver,N I-Non Improver) and whethert herewass edation ornot(y-yes,n-no). Table 2s hows the meano verall scoreand the mean subsection scoreson the TFES beforeand afterz olpidem. The overall meanimprovementafterzolpidem on the TFES was11.3%,areduction from 73.4/100 to62.1/100 (p =0.0001). 10out of 23 patients (43%) improved on brain SPECT scanafterzolpidem while therewasno improvementon the SPECT scani n1 3/23 patients.Inthe 10/23 improvers,the meanTFES scoref ell by19.4 % (± 16.75) compared with5 .08% (± 5.17)i nthe 13/23 non improvers (p =0.0081) (Fig. 1,2 ).
3.Results
Patients
3.2Clinicalscale
Discussion
Thisisthe first prospective,multi-patient,c linicalstudy tod emonstratethe beneficiale ffectof zolpidem in established brain damage. Our patients'i njuriesw eresevere,showing adegree of dependencybys coring less than1 00/100 on the Barthel Index(BI). The BI isa widelyu sed clinicaltool tom easuren eurologicald isability,b ut isless sensitivef oractivitiesof dailyliving. Wechosethe equallyestablished,but moresensitiveTinettiscale (TFES)f ort hispurpose. Itr equirespatients orcarers torateconfidencei nten activitiesof dailyliving on ascale of 1meaning most confidentto10mean-ing least confident.The scale indirectlyr atesneurologicald isability becausethisislinked tol acko fconfidencei nsuchactivities [16] .Italsoi sameasuref or the risko ff alling,a ni mportantconsideration in thispatientgroup [5] . Wef ound ahighlys ignificantimprovement(p =0.0001) in the mean TFES scoreafterz olpidem in our 23 patients,10of whom improved by10%o rmoreand 6by2 0%o r more. A10%i mprovementist he equivalentof apatientprogressing from inability top erformatask( 1/ 10)toscoring full marks(10/10) whichrepresents ac learand remarkable clinicali mprovement. Thereweref our patients in the MinimallyConscious Stateand one patientin the Locked in Syndrome included in thiss tudy.The chosen TinettiScale maynot bethe most sensitivewayt oe valuatethesep atients, but thereareaspects of confidencei nsuchp atients whichcanbewell rated on Tinetticriteria, forexample "taking ab atho rs hower,getting in and out of bed and getting in and out of achair".
CNS-activeDrugs·Hypnotics·Psychotropics·Sedatives
Wei ncluded SPECT scansin thiss tudyasobjective markers thatw ould notbed ependenton clinicalrating ors ensitivetop laceboe ffects.Wef ound asignificant meanTFES improvementin the 10patients withi mproved SPECT scansw hichcontrasted with1 3non improvers (19.4 % versus 5.1 %,p=0.0081). Thisindicatesa link between clinicaland SPECT scani mprovements.
While placeboo rpositivecontrolsarei dealm arkers forcomparativestudies,theirr ole in thiss tudyappeared questionable duetothe obvious sedativee ffect of zolpidem. Inthisstudy11 of the 23 patients (48 %) reported asedativeeffectof zolpidem thatwould nothave occurred on placebo,sorendering astatisticalcomparison between them invalid. Apositivecontrol in the form of anothers edativewould riski njuriesfrom increased fallsbecaused aytime sedation would havebeen unavoidable foraperiod of severalweeks.Inp atients who lackconfidencef oractivitieslike descending stepsw e considered thist obee thicallyquestionable during a proof of principle studyw hen the beneficiale ffectof the test treatmentr emained in question. Having now established thatz olpidem hasane ffectt hatprobably decreasesr isktof urtherinjury rathert hani ncreasing it,our reservationsforfuturetrialsw ill bed iminished.
Wethink itimprobable thatt he clinicaland SPECT improvements wereaplaceboe ffect.Firstly,improvements on the TinettiScale werel arge and clinically moreimpressivethanwould beexpected from placebos. Theywere20 %and overin 6of the 23 patients whichis the equivalentof patients recovering from no confidencewhatsoevert of ull confidencei natleast 2activ-ities.Secondly,a ll patients weree nrolled atleast 6monthsaftert heirbrain injury,in astable phase, whichm ade spontaneous improvements most unlikely. Thirdly,a part from the objectiven atureo fscanst hat detectperfusion changesw ithin the brain,wee nsured thats cansw erei nterpreted blindlyand randomlyby three independentassessors,who hadn ok nowledge of the clinicalrating scores.
Weattempted toe liminateselection biasbyenrolling consecutivelypresenting patients regardless of age,genderorcauseo fi njury.Thisproduced awide variety of injury type and cause,whichwasnotamajorconcern becausep revious anecdotalreports haveshownbeneficialzolpidem effects in awide spectrumo fclinicalf eaturesand causes.Forexample the first reported patient wascategorized tothe VegetativeStateafteratraumatic brain injury,withalowGlasgowComaS cale scoreo f9 thatbecame anormal15afterzolpidem [4] .Bycontrast, Hall etal. found improvements afterz olpidem in subtle impairments of wordrecognition and cognitivefunction in afullyconscious and independentstroke patient [17] .
99m TcHMPAO SPECT scanscand etects mall changes in cerebralp erfusion sotheyareo ften moresensitive thanclinicalrating scales.Theydetectchangesr egardless of the type of symptom. Improvements afterz olpidem havebeen detected previouslyin SPECT and PET brain scans,c orrelating withclinicali mprovements [4] [5] [6] .The activated areasdo notshowatypicallocation or distribution patternand vary between patients,probablybecausesitesof injury arealsoh ighlyv ariable. However,the timing and natureo fthe changesclearly indicatethattheyarepart of the effectof zolpidem. This wasshownpharmacologicallyin ananimalstudywhere the effectof zolpidem activation wasblocked byflumazenil,a nantagonist atbenzodiazepine receptors,which includest he omega-1 sitesatw hichzolpidem acts [18] . Wed id notfind aperfectmatchbetween SPECT and TFES improvement,sincetherewere3improvers on SPECT scanwho hadn od etectable clinicali mprove- menton the TFES (patients de,ktand va). Thismay havebeen duetoalackofsensitivity totheirs ymptoms in the TFES, whichsuggests thatSPECT scansmaybe helpfuli ni dentifying possible responders when clinical changesarenotobvious. Brain SPECT scanscanbei nterpreted visuallybyhumano bservers ors emi-quantitativelyu sing computerized image comparisonss uchasBRASS, SPM orVOI techniques [19 -21] .However,neithermethod provides anundisputed gold standardf oraccuracyand validity sincen ecessary smoothing techniquesforexample may influencethe accuracyof quantitativeSPECT techniques [22] .Fort he uniquep urposeo fthiss tudy,namelyt o identifyaresponseafterzolpidem in the same subject,a visualassessmentbyt hree independent,b lind-to-treatmentassessors wasthoughtthe most appropriate.
Itisunusualthatasedativemedication suchaszolpidem canp roduceactivation of suppressed brain tissue. Ithasbeen postulated thatt he observed long termp hysiologicalbrain suppression thatoccurs afterbrain injury isaprotectiveGABAergiceffect,probablycaused byoversensitivem odified GABA receptors when GABA reservesbecome depleted afterinjury.Zolpidem counters thisr eceptormodification and normalisesbrain function [5] .
Inconclusion our 23 patients produced a43%re-sponseratetozolpidem therapyaccording tothe brain SPECT scansand clear,significantbeneficialclinicale ffects.Furtherresearchshould nowbeundertaken in the formo faplacebocontrolled trial,toconfirmtheseresults in established brain damage,whetheritbed ueto stroke,traumaticb rain injury orothercauses.
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